MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, August 27, 2016

Novartis (NVS) Reports Positive Phase III Results on MS Drug


Click here to receive MS news via e-mail

Novartis AG NVS announced positive results from the phase III EXPAND study on its pipeline candidate, BAF312 (siponimod).
The randomized, double-blinded, placebo-controlled study was evaluating the efficacy and safety of once-daily oral BAF312 in patients suffering from secondary progressive multiple sclerosis (SPMS).
Results showed that the study met its primary endpoint of a reduction in the risk of disability progression, compared with placebo.
Data from the study will be presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London next month.

MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: